The study of visinin-like protein-1 concentration in blood on the mild cognitive impairment and Alzheimer disease

Objective To explore the visinin-like protein-1 (VILIP-1) levels in the blood in the Alzheimer disease (AD) and mild cognitive impairment (MCI) due to AD patients, and also to explore its feasibility as a biomarker for the early diagnosis of AD and for the detection of progression of AD. Methods Fifty-eighty participants were included: 20 cases for AD group, 19 cases for MCI due to AD group, 19 cases for normal control group. The level of VILIP-1 was tested by the ELISA method. Results The level of VILIP-1 in AD group was significantly higher than that in normal control group and MCI due to AD group: (9.0±2.9) ng/L vs. (3.3±1.7) and (6.5±3.1) ng/L, and that in MCI due to AD group was significantly higher than that in normal group, there were statistical differences (P<0.01) . The MMSE score in AD group was significantly lower than that in normal group and MCI due to AD group: (15±3) scores vs. (27±2) and (23±2) scores, and that in MCI due to AD group was significantly lower than that in normal group, there were statistical differences (P<0.01) . The level of VILIP-1 was negatively correlated with MMSE score (r=0.463,P<0.01) , but positively correlated with age (r=0.417,P=0.01) . Conclusions With the progression of the disease, the cognitive impairment of the AD patient is decreasing. VILIP-1 increased in the blood of the patients of AD and MCI due to AD. It means that the blood VILIP-1 could be a new and potential biomarker for the early diagnosis of AD, and it may be clinical useful for the early diagnosis and effective detection of AD to some extent. Key words: Alzheimer disease; Cognitive impairment; Visinin-like protein-1; Early diagnosis